CoChat

Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia

Nesto, Richard, Fain, Randi, Li, Yuhan, Shanahan, William · 2016 · Postgraduate Medicine

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Lorcaserin is a selective 5-HT2C (5-hydroxytryptamine 2C) receptor agonist indicated for weight management. Here, we assess the impact of lorcaserin on progression from prediabetes to type 2 diabetes (T2D) and on reversion from prediabetes to euglycemia. METHODS: This is a post hoc analysis of pooled data from two Phase 3 studies, BLOOM and BLOSSOM (N = 6136), evaluating the impact of lorcaserin on weight and glycemic parameters over 52 weeks in the subpopulation of obese/overweight subjects with prediabetes, alternately defined by fasting plasma glucose (FPG) 100-125 mg/dl or glycated hemoglobin (HbA1c) 5.7-6.4% at baseline. RESULTS: At Week 52, in the subpopulation with prediabetes, nearly twice as many lorcaserin-treated subjects achieved ≥5% weight loss versus placebo (HbA1c: 55.6% vs. 27.5%, p < 0.001; FPG: 52.8% vs. 28.8%, p < 0.001), and a significantly lower percentage of lorcaserin-treated subjects progressed to T2D versus placebo based on HbA1c (lorcaserin 3.2%, placebo 5.0%, p = 0.032) but not FPG (lorcaserin 1.6%, placebo 2.6%, p = 0.227). A significantly greater proportion of lorcaserin-treated subjects versus placebo also reverted to euglycemia based on both HbA1c (lorcaserin 40%, placebo 29.5%, p < 0.001) and FPG (lorcaserin 52.4%, placebo 46.5%, p = 0.047). CONCLUSION: In subjects with prediabetes, lorcaserin may contribute to weight loss and improve glycemic parameters, and thus may help with preventing progression to T2D and promoting reversion to euglycemia. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifiers are NCT00395135 (BLOOM) and NCT00603902 (BLOSSOM).

Overview

Integrity signals

Registry

Crossref · 10.1080/00325481.2016.1178590

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 6

  1. International Diabetes Federation, 2013, IDF Diabetes Atlas
  2. Portero McLellan KC, 2014, Ther Clin Risk Manag, 10, 173
  3. BELVIQ (lorcaserin hydrochloride), 2014, US Prescribing Information
  4. Nesto R, 2014, Diabetes, 63, A27
  5. American Diabetes Association, 2010, Diabetes Care, 33
  6. Alqahtani N, 2013, Int J Prev Med, 4, 1025

Cited by

See all 20

Metadata

Authors
Nesto, R., Fain, R., Li, Y., & Shanahan, W.
Affiliations
  • Lahey Hospital and Medical Center (US)
  • Eisai (United States) (US)
  • Arena Pharmaceuticals (United States) (US)
Corresponding author
Nesto, Richard
Venue
Postgraduate Medicine
Published
2016-05-03
Volume
128
Issue
4
Pages
364-370
ISSN
  • 0032-5481 (ISSN-L)
  • 1941-9260
OpenAlex
W2344286639
Cited by
20
References
28
Citations by year
2024: 2 · 2022: 2 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 4
FWCI
2.97
Type
journal article
Language
en
Open access
closed
Locations
  • Postgraduate Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Arena Pharmaceuticals, Inc
  • Eisai, Inc
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
lorcaserin, prediabetes, type 2 diabetes prevention, 5-HT2C receptor agonist, weight loss, glycemic control, HbA1c, fasting blood glucose, obesity, bloom, flowers, weight management, drug safety and efficacy, adverse events, serious adverse events, cardiovascular safety
MeSH terms
Adult, Benzazepines, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Prediabetic State, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Disease Progression, Serotonin 5-HT2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. https://app.cochat.ai/papers/10.1080/00325481.2016.1178590
The paper
Nesto, R., Fain, R., Li, Y., & Shanahan, W. (2016). Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgraduate Medicine. https://doi.org/10.1080/00325481.2016.1178590

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.